(1H-indol-4-yl)(4-methylpiperazin-1-yl)methanone | 1038988-60-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: (1H-indol-4-yl)(4-methylpiperazin-1-yl)methanone
• 英文别名: 1H-indol-4-yl-(4-methylpiperazin-1-yl)methanone
• CAS: 1038988-60-1
• 化学式: C₁₄H₁₇N₃O
• mdl: MFCD12078510
• 分子量: 243.308
• InChiKey: RTGQAPQOHWHJIR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  18
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.357
• 拓扑面积：
  39.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (1H-indol-4-yl)(4-methylpiperazin-1-yl)methanone 在 N-溴代丁二酰亚胺(NBS) 、 lithium aluminium tetrahydride 、 sodium hydride 作用下， 以 四氢呋喃 、 1,4-二氧六环 为溶剂， 生成 3-bromo-1-(1-naphthylsulfonyl)-4-(4-methylpiperazin-1-ylmethyl)-1H-indole
  参考文献：
  名称：

  Design, synthesis and pharmacological evaluation of 4-(piperazin-1-yl methyl)-N1-arylsulfonyl indole derivatives as 5-HT6 receptor ligands

  摘要：

  4-(Piperazin-1-yl methyl)-N-1-arylsulfonyl indole derivatives were designed and synthesized as 5-HT6 receptor (5-HT6R) ligands. The lead compound 6a, from this series shows potent in vitro binding affinity, good PK profile, no CYP liabilities and activity in animal models of cognition. (c) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.10.057
• 作为产物：
  描述：

  2-甲基-3-硝基苯甲酸 在 氯化亚砜 、 一水合肼 、 N,N-二甲基甲酰胺 作用下， 以 四氢呋喃 、 1,2-二氯乙烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 12.5h， 生成 (1H-indol-4-yl)(4-methylpiperazin-1-yl)methanone
  参考文献：
  名称：

  Design, synthesis and pharmacological evaluation of 4-(piperazin-1-yl methyl)-N1-arylsulfonyl indole derivatives as 5-HT6 receptor ligands

  摘要：

  4-(Piperazin-1-yl methyl)-N-1-arylsulfonyl indole derivatives were designed and synthesized as 5-HT6 receptor (5-HT6R) ligands. The lead compound 6a, from this series shows potent in vitro binding affinity, good PK profile, no CYP liabilities and activity in animal models of cognition. (c) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.10.057

文献信息

• 4-(HETEROCYCLYL)ALKYL-N-(ARYLSULFONYL)INDOLE COMPOUNDS AND THEIR USE AS 5-HT6 LIGANDS
  申请人：Ramakrishna Venkata Satya Nirogi

  公开号：US20100041669A1

  公开（公告）日：2010-02-18

  Compounds including 4-(Heterocyclyl)alkyl-N-(arylsulfonyl)indole compounds of the formula (I), their derivatives, their stereoisomers, their pharmaceutically acceptable salts and pharmaceutically acceptable compositions containing them as well as a process for the preparation of these compounds, their derivatives, their stereoisomers, their pharmaceutically acceptable salts and pharmaceutically acceptable compositions containing them. These compounds are useful in the treatment of various disorders that are related to 5-HT 6 receptor functions. Specifically, the compounds of this invention are also useful in the treatment of various CNS disorders, hematological disorders, eating disorders, diseases associated with pain, respiratory diseases, genito-urological disorders, cardiovascular diseases and cancer.

  化合物包括式(I)的4-(杂环基)烷基-N-(芳基磺酰基)吲哚化合物，它们的衍生物、立体异构体、药学上可接受的盐以及包含它们的药学上可接受的组合物，以及制备这些化合物、它们的衍生物、立体异构体、药学上可接受的盐以及包含它们的药学上可接受的组合物的方法。这些化合物可用于治疗与5-HT6受体功能相关的各种疾病。具体而言，本发明的化合物还可用于治疗各种中枢神经系统疾病、血液学疾病、进食障碍、与疼痛相关的疾病、呼吸系统疾病、泌尿生殖系统疾病、心血管疾病和癌症。
• WO2008/84491
  申请人：——

  公开号：——

  公开（公告）日：——
• 4-(HETEROCYCLYL)ALKYL-N-(ARYLSULFONYL) INDOLE COMPOUNDS AND THEIR USE AS 5-HT6 LIGANDS
  申请人：Suven Life Sciences Limited

  公开号：EP2121602A1

  公开（公告）日：2009-11-25
• [EN] 4-(HETEROCYCLYL)ALKYL-N-(ARYLSULFONYL) INDOLE COMPOUNDS AND THEIR USE AS 5-HT6 LIGANDS<br/>[FR] COMPOSÉS 4-(HÉTÉROCYCLYL)ALKYL-N-(ARYLSULFONYL)INDOLE ET LEUR UTILISATION EN TANT QUE LIGANDS DU 5-HT6
  申请人：SUVEN LIFE SCIENCES LTD

  公开号：WO2008084491A1

  公开（公告）日：2008-07-17

  [EN] The present invention relates to novel 4-(Heterocyclyl)alkyl-N- (arylsulfonyl)indole compounds of the formula (I), their derivatives, their stereoisomers, their pharmaceutically acceptable salts and pharmaceutically acceptable compositions containing them. The present invention also relates to a process for the preparation of above said novel compounds, their derivatives, their stereoisomers, their pharmaceutically acceptable salts and pharmaceutically acceptable compositions containing them. These compounds are useful in the treatment of various disorders that are related to 5-HT₆ receptor functions. Specifically, the compounds of this invention are also useful in the treatment of various CNS disorders, hematological disorders, eating disorders, diseases associated with pain, respiratory diseases, genito-urological disorders, cardiovascular diseases and cancer.
  [FR] La présente invention concerne de nouveaux composés 4-(hétérocyclyl)-alkyl-N-(arylsulfonyl)indole de formule (I), leurs dérivés, leurs stéréo-isomères, leurs sels acceptables sur le plan pharmaceutique et des compositions acceptables sur le plan pharmaceutique les contenant. La présente invention concerne également un procédé de préparation desdits nouveaux composés cités ci-dessus, de leurs dérivés, de leurs stéréo-isomères, de leurs sels acceptables sur le plan pharmaceutique et des compositions acceptables sur le plan pharmaceutique les contenant. Ces composés sont utiles dans le traitement de divers troubles qui sont associés aux fonctions du récepteur 5-HT₆. De manière spécifique, les composés de cette invention sont également utiles dans le traitement de divers troubles du SNC, de troubles hématologiques, de troubles de l'alimentation, de maladies associées à la douleur, de maladies respiratoires, de troubles génito-urinaires, de maladies cardiovasculaires et du cancer.
• Design, synthesis and pharmacological evaluation of 4-(piperazin-1-yl methyl)-N1-arylsulfonyl indole derivatives as 5-HT6 receptor ligands
  作者：Ramakrishna V.S. Nirogi、Rajeshkumar Badange、Ramasastri Kambhampati、Anil Chindhe、Amol D. Deshpande、Vinaykumar Tiriveedhi、Vishwottam Kandikere、Nageswararao Muddana、Renny Abraham、Mukkanti Khagga

  DOI：10.1016/j.bmcl.2012.10.057

  日期：2012.12

  4-(Piperazin-1-yl methyl)-N-1-arylsulfonyl indole derivatives were designed and synthesized as 5-HT6 receptor (5-HT6R) ligands. The lead compound 6a, from this series shows potent in vitro binding affinity, good PK profile, no CYP liabilities and activity in animal models of cognition. (c) 2012 Elsevier Ltd. All rights reserved.